A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Esophageal Cancer Clinical Trial

Official title:

A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02639065
• Other study ID #: BTCRC-ESO14-012
• Status: Completed
• Phase: Phase 2
• Start date: April 27, 2016
• Est. completion date: June 9, 2021

Study information

• Verified date: September 2023
• Source: Big Ten Cancer Research Consortium
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II, open-label, single arm, single-stage study. A total of 23 evaluable patients will be enrolled. If total number of patients free of disease relapse at 1 year is less than or equal to 15, the drug would not be considered for further study in this setting. After six patients are treated with at least one dose of study drug, they will be observed for a minimum of 60 days. During the 60-day observation period, further accrual will be halted to evaluate "unacceptable toxicities warranting early closure of the trial" defined as: - Any definitive durvalumab-related death. A durvalumab-related death will be continuously monitored throughout the trial and the trial will be suspended for re-evaluation whenever such an event is confirmed. - Any unexpected and previously unreported grade 4 toxicities definitely related to durvalumab.

Description:

OUTLINE: This is a multi-center trial. INVESTIGATIONAL TREATMENT: Subjects will receive durvalumab 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence. The following baseline labs must be completed within 28 days prior to registration for protocol therapy: Hematopoietic: - White blood cell count (WBC) > 3 K/mm^3 - Hemoglobin (Hgb) > 9 g/dL. Transfusion is allowed, if needed, since patients are post esophagectomy. - Platelets > 100 K/mm^3 - Absolute neutrophil count (ANC) ≥ 1.5 K/mm^3 Renal: - Calculated creatinine clearance of >/= 40 cc/min using the Cockcroft-Gault formula or by 24-hour urine collection. Hepatic: - Bilirubin ≤ 1.5 x upper limit of normal (ULN) - Aspartate aminotransferase (AST, SGOT)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: June 9, 2021
• Est. primary completion date: December 9, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subject must meet all of the following applicable inclusion criteria to participate in this

study:

• Written informed consent and HIPAA authorization for release of protected health information obtained from the subject prior to performing any protocol-related procedures, including screening evaluations. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
• Age = 18 years at the time of consent.
• ECOG Performance Status of 0-1 within 28 days prior to registration for protocol therapy.
• Females of childbearing potential and males must be willing to use two effective methods of contraception (see the protocol) from the time consent is signed until 3 months after treatment discontinuation.
• Females of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration for protocol therapy. NOTE: Female subjects are considered of child bearing potential unless they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are =60 years old and naturally postmenopausal for at least 12 consecutive months. See the protocol.
• Histological evidence of persistent residual esophageal adenocarcinoma including gastroesophageal junction adenocarcinoma following definitive concurrent chemoradiotherapy (carboplatin and paclitaxel or cisplatin and 5-FU) in the surgical sample (esophagus or lymph node or both) obtained at the time of esophagectomy. NOTE: Persistent residual disease is defined as follows (modified from College of American

Pathologists Guidelines):

• No residual tumor (Grade 0, complete response, 0% tumor). This group will not be included in this study.
• Marked response (Grade 1, 0-<10% residual tumor)
• Moderate response (Grade 2, 10-50% residual tumor)
• No definite response (Grade 3, >50% residual tumor)
• Minimum of 1 month and maximum of 3 months from surgical resection with no evidence of disease progression at the time of enrollment.
• Must have adequately recovered from surgery as judged by the treating investigator.
• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

• Prior therapy with a PD-1, PD-L1, or CTLA-4 inhibitor or cancer-specific vaccine therapy.
• Evidence of active autoimmune disease requiring systemic treatment within preceding 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Exceptions to this rule include vitiligo, resolved childhood asthma/atopy, requirement of intermittent bronchodilators or local steroid injections, hypothyroidism stable on hormone replacement, psoriasis not requiring systemic treatment (within the past 2 years), Graves's disease and Sjogren's syndrome.
• Prior malignancy is not allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, Gleason score = 7 prostate cancers, or other cancer for which the subject has been disease-free for at least 3 years.
• Active or prior documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis).
• Presence of interstitial lung disease or history of pneumonitis requiring treatment with corticosteroids.
• Patients with diagnosis of primary immunodeficiency.
• Patients receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy within 28 days prior to registration for protocol therapy. Exceptions include intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
• History of allogeneic organ or stem cell transplant.
• Receipt of live attenuated vaccine within 30 days prior to registration for protocol therapy.
• Mean QT interval corrected for heart rate (QTc) > 470 msec calculated from 3 ECGs by Bazett's Correction.
• Ventricular arrhythmias requiring medication(s).
• Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, or active bleeding diatheses.
• History of psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent.
• Known HIV infection or chronic hepatitis B or C.
• Known history of previous clinical diagnosis of tuberculosis.
• Clinically significant infections as judged by the treating investigator. Clinically significant is defined as an active infection requiring IV antibiotics.
• Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued. In addition, breast milk cannot be stored for future use while the mother is being treated on study.
• Treatment with any investigational agent within 28 days prior to registration for protocol therapy.
• History of hypersensitivity to durvalumab or any excipient.
• Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
• Previous enrollment in the present study.

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms

Intervention

Drug:
• Durvalumab
1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.

Locations

Country	Name	City	State
United States	University of Michigan Health System	Ann Arbor	Michigan
United States	Indiana University Melvin and Bren Simon Cancer Center	Indianapolis	Indiana
United States	Unversity of Iowa Hospital and Clinics	Iowa City	Iowa

Sponsors (4)

Lead Sponsor	Collaborator
Shadia Jalal, MD	AstraZeneca, Big Ten Cancer Research Consortium, MedImmune LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With One-Year Relapse Free Survival (RFS) With Post-Operative Durvalumab	Relapse free survival is defined as time from the date of surgery until the criteria for disease relapse is met, per Response Evaluation Criteria In Solid Tumors (RECIST 1.1), or death occurs.; Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started The percentage of subjects who attained relapse free survival for 1 year and 95 % confidence interval has been reported here.	From the date of surgery until disease relapse or death up to a maximum of 40 months.
Secondary	Number of Patients With Adverse Events as a Measure of Safety and Tolerability	One of the secondary objective in this study is to assess toxicity and tolerability of durvalumab following trimodality therapy in patients with esophageal cancer. Adverse events were recorded from the time of consent for at least 90 days after treatment discontinuation, per Common Terminology Criteria for Adverse Events (CTCAE) v4. Events were assessed at every visit at an interval of 4 weeks.; Adverse Event severity grades can be described as follows : Grade 1 indicates a mild event; Grade 2 indicates a moderate event; Grade 3 indicates a severe event; Grade 4 indicates a potentially life-threatening event; Grade 5 indicates death	From the time of consent until 90 days after last dose of durvalumab up to a maximum of 15 months.

External Links

•   Big Ten Cancer Research Consortium Website